HUTCHMED has ambitious near- and medium-term growth plans, centred on its novel oncology products, to initially create a sizeable commercial organisation addressing Greater China whilst also building the appropriate infrastructure to address key global markets. The first product wave - Elunate (fruquintinib), Orpathys (savolitinib) and Sulanda (surufatinib) - are expected to post FY22 revenues of $160-$190m in China. The second and third waves of innovative programmes are progressing through development, with highly encouraging clinical profiles. This note details the status and relative importance of the key programmes and complements our September 2022 Outlook. Our valuation is $5.51bn/ £4.59bn/ HK$43.08bn, equivalent to $31.89/ADS or 531p/HK$49.83 per share.
06 Sep 2022
HUTCHMED: Rich and diverse pipeline with multiple waves of growth
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
HUTCHMED: Rich and diverse pipeline with multiple waves of growth
AstraZeneca PLC (AZN:LON), 10,689 | CK Hutchison Holdings Ltd (1:HKG), 0 | Eli Lilly and Company (LLY:NYS), 0 | HUTCHMED (China) Limited Sponsored ADR (HCM:NAS), 0 | Ipsen SA (IPN:PAR), 0 | Eli Lilly and Company (0Q1G:LON), 0 | Ipsen SA (0MH6:LON), 0
- Published:
06 Sep 2022 -
Author:
Franc Gregori | Lala Gregorek | Philippa Gardner -
Pages:
31
HUTCHMED has ambitious near- and medium-term growth plans, centred on its novel oncology products, to initially create a sizeable commercial organisation addressing Greater China whilst also building the appropriate infrastructure to address key global markets. The first product wave - Elunate (fruquintinib), Orpathys (savolitinib) and Sulanda (surufatinib) - are expected to post FY22 revenues of $160-$190m in China. The second and third waves of innovative programmes are progressing through development, with highly encouraging clinical profiles. This note details the status and relative importance of the key programmes and complements our September 2022 Outlook. Our valuation is $5.51bn/ £4.59bn/ HK$43.08bn, equivalent to $31.89/ADS or 531p/HK$49.83 per share.